(Q45722783)

English

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

scientific article published on 23 June 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 December 2017

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel (English)

1 reference

Europe PubMed Central

15 December 2017

Françoise Brun-Vézinet

2

object named as

Françoise Brun-Vézinet

1 reference

Europe PubMed Central

15 December 2017

Bonaventura Clotet Sala

3

object named as

Bonaventura Clotet

1 reference

Europe PubMed Central

15 December 2017

Scott M. Hammer

8

object named as

Scott M Hammer

1 reference

Europe PubMed Central

15 December 2017

Daniel Kuritzkes

5

object named as

Daniel R Kuritzkes

1 reference

Europe PubMed Central

15 December 2017

author name string

Martin S Hirsch

1

1 reference

Europe PubMed Central

15 December 2017

Brian Conway

4

1 reference

Europe PubMed Central

15 December 2017

Richard T D'Aquila

6

1 reference

Europe PubMed Central

15 December 2017

Lisa M Demeter

7

1 reference

Europe PubMed Central

15 December 2017

Victoria A Johnson

9

1 reference

Europe PubMed Central

15 December 2017

Clive Loveday

10

1 reference

Europe PubMed Central

15 December 2017

John W Mellors

11

1 reference

Europe PubMed Central

15 December 2017

Donna M Jacobsen

12

1 reference

Europe PubMed Central

15 December 2017

Douglas D Richman

13

1 reference

Europe PubMed Central

15 December 2017

language of work or name

0 references

publication date

23 June 2003

1 reference

Europe PubMed Central

15 December 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

15 December 2017

37

1 reference

Europe PubMed Central

15 December 2017

113-128

1 reference

Europe PubMed Central

15 December 2017

1

1 reference

Europe PubMed Central

15 December 2017

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Therapeutic drug monitoring in HIV infection: current status and future directions

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase.

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase n

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Impact of drug resistance mutations on virologic response to salvage therapy

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Knowledge of genotypic resistance mutations among providers of care to patients with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Antiretroviral-drug resistance among patients recently infected with HIV.

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study.

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Acute HIV infection: impact on the spread of HIV and transmission of drug resistance.

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Changes in the rate of genotypic resistance to antiretroviral drugs in Spain

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions

1 reference

https://api.crossref.org/works/10.1086%2F375597

21 January 2018

Identifiers

1 reference

Europe PubMed Central

15 December 2017

1 reference

Europe PubMed Central

15 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45722783&oldid=2078957672"